Sun Pharma reports 15.86% drop in carbon emissions for FY26
- Absolute Scope 1 and 2 carbon emissions reduced by 15.86% against the 2020 baseline
- Female representation in the global workforce reached 17.97%, with 13.44% in top management
- CSR spend totaled INR 2,068 million, impacting nearly 2.23 million lives in India
- Renewable energy sources contributed 43% to total energy consumption during FY26
- Board meeting attendance averaged 95.24%, with 50% independent directors on the board
*this image is generated using AI for illustrative purposes only.
Sun Pharmaceutical Industries Limited released its ESG Overview for FY26, detailing significant progress in environmental sustainability and corporate governance. The report highlights a 15.86% reduction in absolute Scope 1 and 2 carbon emissions compared to the 2020 baseline, alongside a 48.64% decrease in specific intensity.
The company’s reporting boundary now covers 44 manufacturing locations and R&D centers, representing approximately 97% of revenues for EHS indicators. This expansion from the previous 79% coverage ensures a more comprehensive assessment of operational impacts across its global footprint.
Environmental performance metrics
Sun Pharma achieved a 16.05% reduction in absolute water consumption and a 48.72% decrease in specific intensity against the 2020 baseline. Renewable energy sources accounted for 43% of total energy consumption during the fiscal year.
| Metric | FY26 Performance | Baseline Year | Target Year |
|---|---|---|---|
| Absolute Carbon Emissions (Scope 1+2) | -15.86% | 2020 | 2030 |
| Specific Carbon Intensity | -48.64% | 2020 | 2030 |
| Absolute Water Consumption | -16.05% | 2020 | 2030 |
| Specific Water Intensity | -48.72% | 2020 | 2030 |
| Renewable Energy Share | 43% | N/A | N/A |
The company maintained zero environmental non-compliance issues and reported zero fines or penalties related to biodiversity violations. Hazardous waste co-processing reached 37.93%, while 73.24% of total waste was diverted from landfill through recycling, reuse, or co-processing.
Social and governance highlights
In terms of social impact, Sun Pharma recorded an INR 2,068 million CSR spend, touching nearly 2.23 million lives in India. Female representation across the global workforce stood at 17.97%, with women holding 13.44% of top management positions. The company reported zero cases of corruption, bribery, or customer privacy data breaches.
Governance structures remained robust, with an average board meeting attendance of 95.24% and 50% independent directors on the board. The CEO-to-employee pay ratio was calculated at 119.17, reflecting compensation structures aligned with global best practices.
What the numbers show
A notable divergence appears between absolute emission reductions and specific intensity improvements. While absolute emissions fell by 15.86%, specific intensity dropped by 48.64%. This disparity suggests that revenue growth outpaced the rate of absolute emission reduction, indicating that while operational efficiency improved significantly, total output volume increased substantially. The expansion of the reporting boundary to include more sites likely contributed to the rise in absolute figures, yet the sharp decline in intensity underscores effective decarbonization per unit of revenue.
Historical Stock Returns for Sun Pharmaceutical
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.47% | -0.21% | -2.86% | +3.98% | +17.54% | +140.61% |
How will Sun Pharma accelerate its decarbonization efforts to close the gap between current intensity improvements and its 2030 absolute emission targets?
What specific capital expenditure plans are in place to increase the renewable energy share from 43% toward higher sustainability benchmarks?
Will the expansion of ESG reporting coverage to 97% of revenues trigger stricter regulatory scrutiny or investor expectations for Indian pharmaceutical peers?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
